Company slashes jobs by half

Posted 19 April 2024 PM

News that one company had been forced to slash its entire workforce by half in order to progress its CAR T therapy was our top story this week.

ASX-listed Imugene announced it's slashing its headcount by 50 per cent through the sale of its North Carolina cell therapy manufacturing facility to Kincell Bio. The deal will see Florida-based Kincell manufacture Imugene's recently acquired allogeneic CD19 CAR T-cell therapy azer-cell to support ongoing clinical trials. It also extends the company's "cash runway" to 2026. See how much the deal was worth in: Pharma to cut 50% of staff 

To see the whole article, please login